DK0833611T3 - Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf - Google Patents
Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling herafInfo
- Publication number
- DK0833611T3 DK0833611T3 DK96921197T DK96921197T DK0833611T3 DK 0833611 T3 DK0833611 T3 DK 0833611T3 DK 96921197 T DK96921197 T DK 96921197T DK 96921197 T DK96921197 T DK 96921197T DK 0833611 T3 DK0833611 T3 DK 0833611T3
- Authority
- DK
- Denmark
- Prior art keywords
- glass
- active agent
- composition
- pct
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Processing Of Solid Wastes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502244A SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | A composition and a process for the preparation thereof |
| PCT/SE1996/000806 WO1997000670A1 (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0833611T3 true DK0833611T3 (da) | 2001-10-08 |
Family
ID=20398685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96921197T DK0833611T3 (da) | 1995-06-20 | 1996-06-19 | Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6083518A (xx) |
| EP (1) | EP0833611B1 (xx) |
| JP (1) | JP4020331B2 (xx) |
| AT (1) | ATE204466T1 (xx) |
| AU (1) | AU695622B2 (xx) |
| CA (1) | CA2225286C (xx) |
| DE (2) | DE69614689T2 (xx) |
| DK (1) | DK0833611T3 (xx) |
| ES (1) | ES2118677T3 (xx) |
| HK (1) | HK1008774A1 (xx) |
| NZ (1) | NZ311208A (xx) |
| PT (1) | PT833611E (xx) |
| SE (1) | SE9502244D0 (xx) |
| WO (1) | WO1997000670A1 (xx) |
| ZA (1) | ZA965237B (xx) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136814A (en) * | 1997-12-08 | 2000-10-24 | Fujisawa Usa, Inc. | Aqueous acyclovir product |
| SE9801705D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
| SE9801704D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
| WO2001021259A2 (en) * | 1999-09-21 | 2001-03-29 | Emory University | Use and compositions for treating platelet-related disorders using anagrelide |
| ATE329579T1 (de) * | 1999-11-12 | 2006-07-15 | Abbott Lab | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| JP4512700B2 (ja) * | 2003-06-02 | 2010-07-28 | トーアエイヨー株式会社 | アシクロビル含有水溶液製剤 |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| CA2560513A1 (en) | 2004-04-08 | 2005-12-01 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| KR101405545B1 (ko) | 2005-11-28 | 2014-07-03 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| GB2432528B (en) * | 2005-11-29 | 2011-04-06 | Ian Ripley | Anti-viral compositions comprising flavanone glycosides and fruit acids |
| PL2005958T3 (pl) * | 2006-03-08 | 2013-11-29 | Nihon Nohyaku Co Ltd | Kompozycja farmaceutyczna do stosowania zewnętrznego |
| JP5184341B2 (ja) * | 2006-03-08 | 2013-04-17 | 日本農薬株式会社 | 外用の医薬組成物 |
| US8058303B2 (en) | 2006-03-08 | 2011-11-15 | Nihon Nohyaku Co, Ltd | Pharmaceutical composition for external use |
| AU2007260739A1 (en) * | 2006-06-14 | 2007-12-21 | Dr. Reddy's Laboratories Limited | Topical compositions |
| PL2529621T3 (pl) | 2006-09-22 | 2017-06-30 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej brutona |
| KR100721126B1 (ko) | 2006-12-28 | 2007-05-23 | (주)바이오앤에이치엔티 | 모기 기피제 조성물 |
| KR20100075476A (ko) * | 2007-09-05 | 2010-07-02 | 가부시키가이샤 폴라 파마 | 항진균 조성물 |
| US20100204293A1 (en) * | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
| EP2191828B1 (en) * | 2007-09-05 | 2016-08-10 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
| AU2008299220B2 (en) | 2007-09-10 | 2011-07-21 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP5421901B2 (ja) | 2008-03-31 | 2014-02-19 | 国立大学法人広島大学 | エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物 |
| GB2460915B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| US7981925B2 (en) | 2008-08-27 | 2011-07-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EA021943B1 (ru) * | 2009-01-09 | 2015-10-30 | Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг | Способ изготовления вагинального суппозитория |
| WO2010093992A1 (en) * | 2009-02-13 | 2010-08-19 | Topica Pharmaceuticals, Inc | Anti-fungal formulation |
| KR101409792B1 (ko) | 2009-04-09 | 2014-06-19 | 니혼노야쿠가부시키가이샤 | 항진균성 약제학적 조성물 |
| JP5688405B2 (ja) | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
| WO2011024620A1 (en) | 2009-08-25 | 2011-03-03 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| ES2602475T3 (es) | 2010-04-15 | 2017-02-21 | Tracon Pharmaceuticals, Inc. | Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER |
| WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| JP5933544B2 (ja) | 2010-07-26 | 2016-06-08 | バイオマトリカ， インコーポレーテッド | 外界温度で出荷および貯蔵中の血中ｄｎａ、ｒｎａおよびタンパク質ならびに他の生体試料を安定化させるための組成物 |
| MX337711B (es) | 2010-08-27 | 2016-03-15 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
| WO2015054283A1 (en) | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| KR20160093675A (ko) | 2013-12-05 | 2016-08-08 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제의 억제제 |
| US20150224077A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders |
| EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
| EP3134418A4 (en) | 2014-04-23 | 2018-01-03 | The Research Foundation for The State University of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
| CN106572650B (zh) | 2014-06-10 | 2021-08-31 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
| US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| SG11201706989SA (en) | 2015-02-27 | 2017-09-28 | Curtana Pharmaceuticals Inc | Inhibition of olig2 activity |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| KR20230145258A (ko) | 2015-12-08 | 2023-10-17 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
| US10851123B2 (en) | 2016-02-23 | 2020-12-01 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| CN109562281B (zh) | 2016-05-25 | 2021-12-17 | 同心镇痛药物公司 | 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉 |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| EA201990508A1 (ru) | 2016-08-26 | 2019-09-30 | Куртана Фармасьютикалс, Инк. | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 |
| CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| JP2019531308A (ja) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 肺線維症の治療のためのクロモリン組成物 |
| US11382897B2 (en) | 2017-11-07 | 2022-07-12 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
| CA3082086A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| CN112040947A (zh) | 2017-12-07 | 2020-12-04 | 密歇根大学董事会 | Nsd家族抑制剂及用其进行治疗的方法 |
| US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
| WO2019236957A1 (en) | 2018-06-07 | 2019-12-12 | The Regents Of The University Of Michigan | Prc1 inhibitors and methods of treatment therewith |
| CA3107433A1 (en) | 2018-07-27 | 2020-01-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
| WO2020044114A2 (en) | 2018-08-29 | 2020-03-05 | Ftf Pharma Private Limited | Methotrexate pharmaceutical composition |
| US20200069742A1 (en) | 2018-08-29 | 2020-03-05 | Myos Rens Technology Inc. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
| US20200108102A1 (en) | 2018-10-03 | 2020-04-09 | Myos Rens Technology Inc. | Spray dried follistatin product |
| NL2021864B1 (en) * | 2018-10-24 | 2020-05-13 | Seranovo B V | Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations |
| JP2022509479A (ja) * | 2018-10-24 | 2022-01-20 | セラノヴォ・ベー・フェー | 経口医薬製剤のための深共晶溶媒プラットフォーム |
| US10925904B2 (en) | 2018-11-06 | 2021-02-23 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
| US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
| US11833186B2 (en) | 2019-02-01 | 2023-12-05 | Myos Corp. | Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals |
| KR20220009373A (ko) | 2019-03-15 | 2022-01-24 | 유니사이시브 테라퓨틱스 인코포레이티드 | 니코란딜 유도체 |
| JP2023533982A (ja) | 2020-07-10 | 2023-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｇａｓ４１阻害剤及びその使用方法 |
| US20240124467A1 (en) | 2020-12-16 | 2024-04-18 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
| TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| WO2023039240A1 (en) | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
| WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
| KR20240128987A (ko) | 2021-12-30 | 2024-08-27 | 바이오메아 퓨전, 인크. | Flt3의 억제제로서의 피라진 화합물 |
| WO2023235618A1 (en) | 2022-06-03 | 2023-12-07 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
| WO2024086613A2 (en) | 2022-10-19 | 2024-04-25 | Myos Corp. | Myogenic compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US33221A (en) * | 1861-09-03 | Improvement in soap | ||
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| USRE33221E (en) | 1982-04-29 | 1990-05-22 | American Dental Association Health Foundation | Dental restorative cement pastes |
| US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
| EP0319988A1 (en) * | 1987-12-09 | 1989-06-14 | Showa Denko Kabushiki Kaisha | External dermatological composition |
| US5215757A (en) * | 1991-03-22 | 1993-06-01 | The Procter & Gamble Company | Encapsulated materials |
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| DE69222182T2 (de) * | 1991-12-18 | 1998-02-26 | Warner Lambert Co | Verfahren für die herstellung einer festen dispersion |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
-
1995
- 1995-06-20 SE SE9502244A patent/SE9502244D0/xx unknown
-
1996
- 1996-06-19 US US08/973,902 patent/US6083518A/en not_active Expired - Lifetime
- 1996-06-19 DE DE69614689T patent/DE69614689T2/de not_active Expired - Lifetime
- 1996-06-19 PT PT96921197T patent/PT833611E/pt unknown
- 1996-06-19 AU AU62473/96A patent/AU695622B2/en not_active Expired
- 1996-06-19 DK DK96921197T patent/DK0833611T3/da active
- 1996-06-19 WO PCT/SE1996/000806 patent/WO1997000670A1/en active IP Right Grant
- 1996-06-19 ES ES96921197T patent/ES2118677T3/es not_active Expired - Lifetime
- 1996-06-19 DE DE0833611T patent/DE833611T1/de active Pending
- 1996-06-19 AT AT96921197T patent/ATE204466T1/de active
- 1996-06-19 JP JP50378997A patent/JP4020331B2/ja not_active Expired - Lifetime
- 1996-06-19 EP EP96921197A patent/EP0833611B1/en not_active Expired - Lifetime
- 1996-06-19 NZ NZ311208A patent/NZ311208A/xx not_active IP Right Cessation
- 1996-06-19 CA CA002225286A patent/CA2225286C/en not_active Expired - Lifetime
- 1996-06-20 ZA ZA965237A patent/ZA965237B/xx unknown
-
1998
- 1998-07-29 HK HK98109537A patent/HK1008774A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1008774A1 (en) | 1999-05-21 |
| NZ311208A (en) | 1999-03-29 |
| DE69614689D1 (de) | 2001-09-27 |
| DE833611T1 (de) | 1999-01-07 |
| ATE204466T1 (de) | 2001-09-15 |
| DE69614689T2 (de) | 2002-06-27 |
| AU6247396A (en) | 1997-01-22 |
| CA2225286A1 (en) | 1997-01-09 |
| PT833611E (pt) | 2002-01-30 |
| ZA965237B (en) | 1997-01-09 |
| CA2225286C (en) | 2003-06-10 |
| SE9502244D0 (sv) | 1995-06-20 |
| EP0833611B1 (en) | 2001-08-22 |
| ES2118677T1 (es) | 1998-10-01 |
| WO1997000670A1 (en) | 1997-01-09 |
| EP0833611A1 (en) | 1998-04-08 |
| ES2118677T3 (es) | 2001-10-16 |
| JP4020331B2 (ja) | 2007-12-12 |
| JPH11508250A (ja) | 1999-07-21 |
| US6083518A (en) | 2000-07-04 |
| AU695622B2 (en) | 1998-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0833611T3 (da) | Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf | |
| HU9603530D0 (en) | Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments | |
| FI103091B1 (fi) | Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi | |
| BR9408377A (pt) | Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto | |
| DE69434626D1 (de) | Transparente flüssigkeit zur verabreichung von verkapselten medikamenten | |
| DK0790824T3 (da) | 2,2-dichloralkancarboxylsyrer, fremgangsmåde til fremstilling deraf, lægemidler indeholdende disse og anvendelse af disse lægemidler til behandling af insulinresistens | |
| PT83872A (de) | Arzneimittel | |
| DK0695171T3 (da) | Lyosfærer indeholdende gonadotropin | |
| IS3966A (is) | Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine | |
| DK0801559T3 (da) | Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum | |
| ATE179164T1 (de) | Hiv-proteaseinhibitoren | |
| DE69906982D1 (de) | Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen | |
| ES2126265T3 (es) | Tableta de accion retardada con un cierto contenido de diclorofenaco de sodio. | |
| PT94685A (pt) | Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem | |
| NZ508074A (en) | Biologically active compositions, and methods for their preparation, comprising a carrier matrix supersaturated with active agent | |
| NO179009C (no) | Analogifremgangsmåte for fremstilling av salter av L-alfa-glyserofosforyl-D-myo-inositol | |
| DE69416034D1 (de) | Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen | |
| EP0305194A3 (en) | Veterinary composition | |
| ATE105570T1 (de) | Modifizierte menschliche anti-rh(d)-antikoerper. | |
| IL117734A (en) | Anellated beta-carbolines their preparation and pharmaceutical compositions containing them | |
| ES2149073B1 (es) | Agente atrayente y procedimiento para el control de la polilla euzophera pinguis (haw.). |